The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
Abstract
Oncogenic activation of the proto-oncogene c- abl in human leukemias occurs as a result of the addition of exons from the gene bcr and truncation of the first abl exon. Analysis of tyrosine kinase activity and quantitative measurement of transformation potency in a single-step assay indicate that variation in bcr exon contribution results in a functional difference between p210 bcr-abl and p185 bcr-abl proteins. Thus, foreign upstream sequences are important in the deregulation of the kinase activity of the abl product, and the extent of deregulation correlates with the pathological effects of the bcr-abl proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Towbin, H., Staehelin, T., & Gordon, J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.9.4350 · Cited by 53,385
Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
GROFFEN, J., STEPHENSON, J., HEISTERKAMP, N., DEKLEIN, A., BARTRAM, C., & GROSVELD, G. (1984) · Cell · doi:10.1016/0092-8674(84)90077-1 · Cited by 1,599
A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia
Klein, A. D., Kessel, A. G. V., Grosveld, G., Bartram, C. R., Hagemeijer, A., Bootsma, D., Spurr, N. K., Heisterkamp, N., Groffen, J., & Stephenson, J. R. (1982) · Nature · doi:10.1038/300765a0 · Cited by 1,378
The Chronic Myelogenous Leukemia-Specific P210 Protein Is the Product of the bcr / abl Hybrid Gene
Ben-Neriah, Y., Daley, G. Q., Mes-Masson, A.-M., Witte, O. N., & Baltimore, D. (1986) · Science · doi:10.1126/science.3460176 · Cited by 806
Self-citationHermans, A., Heisterkamp, N., von Lindern, M., van Baal, S., Meijer, D., van der Plas, D., Wiedemann, L. M., Groffen, J., Bootsma, D., & Grosveld, G. (1987) · Cell · doi:10.1016/0092-8674(87)90007-9 · Cited by 387
McLaughlin, J., Chianese, E., & Witte, O. N. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.18.6558 · Cited by 367
Self-citationUnique Forms of the abl Tyrosine Kinase Distinguish Ph 1 -Positive CML from Ph 1 -Positive ALL
Clark, S. S., McLaughlin, J., Crist, W. M., Champlin, R., & Witte, O. N. (1987) · Science · doi:10.1126/science.3541203 · Cited by 320
Self-citationN-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl.
Jackson, P., & Baltimore, D. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb03397.x · Cited by 278
Konopka, J. B., & Witte, O. N. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.11.3116 · Cited by 250
Self-citationExpression of a Distinctive BCR-ABL Oncogene in Ph 1 -Positive Acute Lymphocytic Leukemia (ALL)
Clark, S. S., McLaughlin, J., Timmons, M., Pendergast, A. M., Ben-Neriah, Y., Dow, L. W., Crist, W., Rovera, G., Smith, S. D., & Witte, O. N. (1988) · Science · doi:10.1126/science.3422516 · Cited by 235
Self-citation
Cited by
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
The molecular biology of chronic myeloid leukemia
Deininger, M. W. N., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.10.3343 · Cited by 1,667
Molecular themes in oncogenesis
Bishop, J. M. (1991) · Cell · doi:10.1016/0092-8674(91)90636-d · Cited by 1,637
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,589
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040258 · Cited by 1,485
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
Deininger, M., Buchdunger, E., & Druker, B. J. (2005) · Blood · doi:10.1182/blood-2004-08-3097 · Cited by 1,253
Hughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218
Inaba, H., Greaves, M., & Mullighan, C. G. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62187-4 · Cited by 1,074
The Methylation Effect in Medicinal Chemistry
Barreiro, E. J., Kümmerle, A. E., & Fraga, C. A. M. (2011) · Chemical Reviews · doi:10.1021/cr200060g · Cited by 1,017
The Myeloproliferative Disorders
Campbell, P. J., & Green, A. R. (2006) · New England Journal of Medicine · doi:10.1056/nejmra063728 · Cited by 915
Imatinib Mesylate — A New Oral Targeted Therapy
Savage, D. G., & Antman, K. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmra013339 · Cited by 844
Druker, B. J., & Lydon, N. B. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9083 · Cited by 707
Translation of the Philadelphia chromosome into therapy for CML
Druker, B. J. (2008) · Blood · doi:10.1182/blood-2008-07-077958 · Cited by 668
Recurrent gene fusions in prostate cancer
Kumar-Sinha, C., Tomlins, S. A., & Chinnaiyan, A. M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2402 · Cited by 664
Weisberg, E., Manley, P. W., Cowan-Jacob, S. W., Hochhaus, A., & Griffin, J. D. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2126 · Cited by 636
Copland, M., Hamilton, A., Elrick, L. J., Baird, J. W., Allan, E. K., Jordanides, N., Barow, M., Mountford, J. C., & Holyoake, T. L. (2006) · Blood · doi:10.1182/blood-2005-07-2947 · Cited by 635
Chronic myeloid leukaemia as a model of disease evolution in human cancer
Melo, J. V., & Barnes, D. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2147 · Cited by 623
Shared and separate functions of polo-like kinases and aurora kinases in cancer
Lens, S. M. A., Voest, E. E., & Medema, R. H. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2964 · Cited by 597
The biology of CML blast crisis
Calabretta, B., & Perrotti, D. (2004) · Blood · doi:10.1182/blood-2003-12-4111 · Cited by 592
Mahon, F. X., Deininger, M. W. N., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.3.1070 · Cited by 584
Thomas, D. A. (2004) · Blood · doi:10.1182/blood-2003-08-2958 · Cited by 571
Skorski, T., Bellacosa, A., Nieborowska‐Skorska, M., Majewski, M., Martinez, R., Choi, J. K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, T. O., et al. (1997) · The EMBO Journal · doi:10.1093/emboj/16.20.6151 · Cited by 567
Ottmann, O. G. (2002) · Blood · doi:10.1182/blood-2001-12-0181 · Cited by 555
Carroll, M., Ohno-Jones, S., Tamura, S., Buchdunger, E., Zimmermann, J., Lydon, N. B., Gilliland, D. G., & Druker, B. J. (1997) · Blood · doi:10.1182/blood.v90.12.4947 · Cited by 554
Bhatia, R., Holtz, M., Niu, N., Gray, R., Snyder, D. S., Sawyers, C. L., Arber, D. A., Slovak, M. L., & Forman, S. J. (2003) · Blood · doi:10.1182/blood-2002-09-2780 · Cited by 547
Li, S., Ilaria, R. L., Million, R. P., Daley, G. Q., & Van Etten, R. A. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1399 · Cited by 501
A robustness-based approach to systems-oriented drug design
Kitano, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2195 · Cited by 488
Ilaria, R. L., & Van Etten, R. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.49.31704 · Cited by 488
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
Weisberg, E., Manley, P., Mestan, J., Cowan-Jacob, S., Ray, A., & Griffin, J. D. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603170 · Cited by 484
Response and Resistance to BCR-ABL1-Targeted Therapies
Braun, T. P., Eide, C. A., & Druker, B. J. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.006 · Cited by 483
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
Deininger, M. W. N., Goldman, J. M., Lydon, N., & Melo, J. V. (1997) · Blood · doi:10.1182/blood.v90.9.3691 · Cited by 482
Imatinib: A Breakthrough of Targeted Therapy in Cancer
Iqbal, N., & Iqbal, N. (2014) · Chemotherapy Research and Practice · doi:10.1155/2014/357027 · Cited by 470
von Bubnoff, N., Schneller, F., Peschel, C., & Duyster, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07679-1 · Cited by 464
Gastrointestinal stromal tumours
Blay, J.-Y., Kang, Y.-K., Nishida, T., & von Mehren, M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00254-5 · Cited by 460
Yanada, M., Takeuchi, J., Sugiura, I., Akiyama, H., Usui, N., Yagasaki, F., Kobayashi, T., Ueda, Y., Takeuchi, M., Miyawaki, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2177 · Cited by 454
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
Schoepfer, J., Jahnke, W., Berellini, G., Buonamici, S., Cotesta, S., Cowan-Jacob, S. W., Dodd, S., Drueckes, P., Fabbro, D., Gabriel, T., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01040 · Cited by 454
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
Hamilton, A., Helgason, G. V., Schemionek, M., Zhang, B., Myssina, S., Allan, E. K., Nicolini, F. E., Müller-Tidow, C., Bhatia, R., Brunton, V. G., et al. (2012) · Blood · doi:10.1182/blood-2010-12-326843 · Cited by 435
Map kinase signaling pathways and hematologic malignancies
Platanias, L. C. (2003) · Blood · doi:10.1182/blood-2002-12-3647 · Cited by 432
Cortes, J., Rousselot, P., Kim, D.-W., Ritchie, E., Hamerschlak, N., Coutre, S., Hochhaus, A., Guilhot, F., Saglio, G., Apperley, J., et al. (2007) · Blood · doi:10.1182/blood-2006-09-046888 · Cited by 416
Skorski, T., Kanakaraj, P., Nieborowska-Skorska, M., Ratajczak, M., Wen, S., Zon, G., Gewirtz, A., Perussia, B., & Calabretta, B. (1995) · Blood · doi:10.1182/blood.v86.2.726.bloodjournal862726 · Cited by 404
Weisberg, E., & Griffin, J. D. (2000) · Blood · doi:10.1182/blood.v95.11.3498 · Cited by 401
The BCR-ABL Story: Bench to Bedside and Back
Wong, S., & Witte, O. N. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104753 · Cited by 399
Self-citationDominant negative MYC blocks transformation by ABL oncogenes
Sawyers, C. L., Callahan, W., & Witte, O. N. (1992) · Cell · doi:10.1016/0092-8674(92)90241-4 · Cited by 397
Self-citationPui, C.-H. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322407 · Cited by 379
Muller, A. J., Young, J. C., Pendergast, A. M., Pondel, M., Landau, N. R., Littman, D. R., & Witte, O. N. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.4.1785 · Cited by 377
Self-citationPui, C., Crist, W., & Look, A. (1990) · Blood · doi:10.1182/blood.v76.8.1449.1449 · Cited by 373
Guilhot, F., Apperley, J., Kim, D.-W., Bullorsky, E. O., Baccarani, M., Roboz, G. J., Amadori, S., de Souza, C. A., Lipton, J. H., Hochhaus, A., et al. (2007) · Blood · doi:10.1182/blood-2006-09-046839 · Cited by 371
Imatinib as a Paradigm of Targeted Therapies
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)91001-9 · Cited by 370
Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib
Deininger, M. W. N., & Druker, B. J. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.4 · Cited by 365
Pendergast, A. M., Muller, A. J., Havlik, M. H., Maru, Y., & Witte, O. N. (1991) · Cell · doi:10.1016/0092-8674(91)90148-r · Cited by 364
Self-citationBischof, D., Pulford, K., Mason, D. Y., & Morris, S. W. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.4.2312 · Cited by 363
Carpino, N., Wisniewski, D., Strife, A., Marshak, D., Kobayashi, R., Stillman, B., & Clarkson, B. (1997) · Cell · doi:10.1016/s0092-8674(00)81840-1 · Cited by 362
Molecular Genetics of Acute Lymphoblastic Leukemia
Armstrong, S. A., & Look, A. T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.047 · Cited by 362
Jiang, X., Zhao, Y., Smith, C., Gasparetto, M., Turhan, A., Eaves, A., & Eaves, C. (2007) · Leukemia · doi:10.1038/sj.leu.2404609 · Cited by 359
Philadelphia ChromosomePositive Leukemias: From Basic Mechanisms to Molecular Therapeutics
Kurzrock, R., Kantarjian, H. M., Druker, B. J., & Talpaz, M. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-10-200305200-00010 · Cited by 345
Leukemia and the disruption of normal hematopoiesis
Sawyers, C. L., Denny, C. T., & Witte, O. N. (1991) · Cell · doi:10.1016/0092-8674(91)90643-d · Cited by 343
Self-citationStrategies to overcome resistance to targeted protein kinase inhibitors
Daub, H., Specht, K., & Ullrich, A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1579 · Cited by 334
The Hsp90 chaperone complex as a novel target for cancer therapy
Goetz, M. P., Toft, D. O., Ames, M. M., & Erlichman, C. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg316 · Cited by 334
The aurora kinases in cell cycle and leukemia
Goldenson, B., & Crispino, J. D. (2015) · Oncogene · doi:10.1038/onc.2014.14 · Cited by 334
Oligomerization of the ABL Tyrosine Kinase by the Ets Protein TEL in Human Leukemia
Golub, T. R., Goga, A., Barker, G. F., Afar, D. E. H., McLaughlin, J., Bohlander, S. K., Rowley, J. D., Witte, O. N., & Gilliland, D. G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.8.4107 · Cited by 324
Self-citationThe BCR/ABL Tyrosine Kinase Induces Production of Reactive Oxygen Species in Hematopoietic Cells
Sattler, M., Verma, S., Shrikhande, G., Byrne, C. H., Pride, Y. B., Winkler, T., Greenfield, E. A., Salgia, R., & Griffin, J. D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002094200 · Cited by 323
Regulation of Btk Function by a Major Autophosphorylation Site Within the SH3 Domain
Park, H., Wahl, M. I., Afar, D. E. H., Turck, C. W., Rawlings, D. J., Tam, C., Scharenberg, A. M., Kinet, J.-P., & Witte, O. N. (1996) · Immunity · doi:10.1016/s1074-7613(00)80417-3 · Cited by 323
Self-citationMcWhirter, J. R., & Wang, J. Y. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05797.x · Cited by 317
Pui, C., Behm, F., & Crist, W. (1993) · Blood · doi:10.1182/blood.v82.2.343.343 · Cited by 315
Thiesing, J. T., Ohno-Jones, S., Kolibaba, K. S., & Druker, B. J. (2000) · Blood · doi:10.1182/blood.v96.9.3195 · Cited by 309
Flying under the radar: the new wave of BCR–ABL inhibitors
Quintás-Cardama, A., Kantarjian, H., & Cortes, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2324 · Cited by 305
Current status of cytogenetic research in childhood acute lymphoblastic leukemia
Raimondi, S. (1993) · Blood · doi:10.1182/blood.v81.9.2237.2237 · Cited by 295
Essafi, A., Fernández de Mattos, S., Hassen, Y. A. M., Soeiro, I., Mufti, G. J., Thomas, N. S. B., Medema, R. H., & Lam, E. W.-F. (2005) · Oncogene · doi:10.1038/sj.onc.1208421 · Cited by 293
Protein tyrosine kinases and cancer
Kolibaba, K. S., & Druker, B. J. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00022-x · Cited by 291
Fusion of ETV6 to Neurotrophin-3 Receptor TRKC in Acute Myeloid Leukemia With t(12;15)(p13;q25)
Eguchi, M., Eguchi-Ishimae, M., Tojo, A., Morishita, K., Suzuki, K., Sato, Y., Kudoh, S., Tanaka, K., Setoyama, M., Nagamura, F., et al. (1999) · Blood · doi:10.1182/blood.v93.4.1355 · Cited by 281
FusionMap: detecting fusion genes from next-generation sequencing data at base-pair resolution
Ge, H., Liu, K., Juan, T., Fang, F., Newman, M., & Hoeck, W. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr310 · Cited by 280
The powerful world of antisense oligonucleotides: From bench to bedside
Quemener, A. M., Bachelot, L., Forestier, A., Donnou‐Fournet, E., Gilot, D., & Galibert, M. (2020) · WIREs RNA · doi:10.1002/wrna.1594 · Cited by 280
McWhirter, J. R., & Wang, J. Y. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.3.1553 · Cited by 276
Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi)
Wilda, M., Fuchs, U., Wössmann, W., & Borkhardt, A. (2002) · Oncogene · doi:10.1038/sj.onc.1205653 · Cited by 276
The nuclear tyrosine kinase c-abl negatively regulates cell growth
Sawyers, C. L., McLaughlin, J., Goga, A., Havlik, M., & Witte, O. (1994) · Cell · doi:10.1016/0092-8674(94)90240-2 · Cited by 275
Self-citationCilloni, D., & Saglio, G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1613 · Cited by 274
Perspectives on the development of a molecularly targeted agent
Druker, B. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00025-9 · Cited by 273
Oda, T., Heaney, C., Hagopian, J. R., Okuda, K., Griffin, J. D., & Druker, B. J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31596-x · Cited by 272
Nieborowska-Skorska, M., Wasik, M. A., Slupianek, A., Salomoni, P., Kitamura, T., Calabretta, B., & Skorski, T. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.8.1229 · Cited by 271
Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib
Haouala, A., Widmer, N., Duchosal, M. A., Montemurro, M., Buclin, T., & Decosterd, L. A. (2011) · Blood · doi:10.1182/blood-2010-07-294330 · Cited by 268
Carroll, M., Tomasson, M. H., Barker, G. F., Golub, T. R., & Gilliland, D. G. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14845 · Cited by 268
Biomarkers for personalized oncology: recent advances and future challenges
Kalia, M. (2015) · Metabolism · doi:10.1016/j.metabol.2014.10.027 · Cited by 265
Wen, S.-T., & Van Etten, R. A. (1997) · Genes & Development · doi:10.1101/gad.11.19.2456 · Cited by 265
The BCR gene encodes a novel serine/threonine kinase activity within a single exon
Maru, Y., & Witte, O. N. (1991) · Cell · doi:10.1016/0092-8674(91)90521-y · Cited by 264
Self-citationKano, Y., Akutsu, M., Tsunoda, S., Mano, H., Sato, Y., Honma, Y., & Furukawa, Y. (2001) · Blood · doi:10.1182/blood.v97.7.1999 · Cited by 262
Specific inhibition of bcr-abl gene expression by small interfering RNA
Scherr, M., Battmer, K., Winkler, T., Heidenreich, O., Ganser, A., & Eder, M. (2003) · Blood · doi:10.1182/blood-2002-06-1685 · Cited by 259
Whitehead, I. P., Campbell, S., Rossman, K. L., & Der, C. J. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(96)00040-6 · Cited by 259
New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance
Kantarjian, H. M., Talpaz, M., Giles, F., O'Brien, S., & Cortes, J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-12-200612190-00008 · Cited by 256
Holtz, M. S., Slovak, M. L., Zhang, F., Sawyers, C. L., Forman, S. J., & Bhatia, R. (2002) · Blood · doi:10.1182/blood.v99.10.3792 · Cited by 253
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Pagliarini, R., Shao, W., & Sellers, W. R. (2015) · EMBO reports · doi:10.15252/embr.201439949 · Cited by 253
Sawyers, C. L., McLaughlin, J., & Witte, O. N. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.1.307 · Cited by 253
Self-citationMulti-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeutics
McAleer, C. W., Long, C. J., Elbrecht, D., Sasserath, T., Bridges, L. R., Rumsey, J. W., Martin, C., Schnepper, M., Wang, Y., Schuler, F., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav1386 · Cited by 199
Bewry, N. N., Nair, R. R., Emmons, M. F., Boulware, D., Pinilla-Ibarz, J., & Hazlehurst, L. A. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0314 · Cited by 150
Metadata
- Authors
- Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N.
- Venue
- Science
- Published
- 1990-03-02
- Volume
- 247
- Issue
- 4946
- Pages
- 1079-1082
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2040396943
- Cited by
- 1,281
- References
- 21
- FWCI
- 16.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.